Recent studies reveal transformative innovations in oncology diagnostics and treatment modalities. AI-driven radiomics and multi-modal models are enhancing detection and prognosis in pancreatic, lung, and oropharyngeal cancers. New integrated spatial multi-omics platforms like TumorXDB facilitate cross-ethnic pan-cancer analyses, deepening biological insights. Gene editing strategies, including CRISPR-enhanced CAR T cells, are overcoming therapeutic resistance in blood cancers. Additionally, novel immunotherapies targeting pathways such as ICAM1 and inflammatory markers offer promising avenues for glioblastoma and ovarian cancer. Collectively, these developments push personalized oncology towards improved outcomes.